In Search of a Real “Targeted” Therapy for Thyroid Cancer

1. Marcia S. Brose

+Author Affiliations

1. Author's Affiliation: Departments of Medicine and Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania

1. Corresponding Author:
   Marcia S. Brose, Departments of Medicine and Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19010. Phone: 215-615-6519; Fax: 215-898-2136; E-mail:brosem@mail.med.upenn.edu

Abstract

Over the past 5 years, patients with progressive radioactive iodine–refractory thyroid cancer have responded to “targeted” multikinase inhibitors, which inhibit angiogenesis and not the tumor cell. Here, selumetinib targets the mitogen-activated protein kinase pathway in papillary thyroid carcinoma and shows limited single-agent activity in the patients with tumors that harbor the ^V600EBRAF mutation. Clin Cancer Res; 18(7); 1–3. ©2012 AACR.

• Received February 17, 2012.
• Accepted February 20, 2012.

• ©2012 American Association for Cancer Research.

This Article

1. Published OnlineFirst March 26, 2012; doi: 10.1158/1078-0432.CCR-12-0153

1. » Abstract
2. Full Text (PDF)